PURPOSE: Deposition of drug emitted from two commercially available inhalers was measured in an in vitro child oral airway model and compared to existing in vivo data to examine the ability of the child model to replicate in vivo deposition. METHODS: In vitro deposition of drug from a QVAR® pressurized metered dose inhaler (pMDI) and Pulmicort® Turbuhaler® dry powder inhaler (DPI) in an Idealized Child Throat (1) and downstream filter was measured using UV spectroscopy and simulated realistic breathing profiles. Potential effects of ambient relative humidity ranging from 10% to 90% on deposition were also considered. RESULTS: In vitro QVAR pMDI deposition in the idealized mouth-throat at 50% RH (39.2 ± 2.3% of delivered dose) compared well (p>0.05) with in vivo extrathoracic deposition in asthmatic children age 8 to 14 (45.8 ± 12.3%). In vitro Turbuhaler DPI deposition in the idealized mouth-throat at 50% RH (69.0 ± 1.5%) matched in vivo extrathoracic deposition (p>0.05) in 6 to 16 year old children with cystic fibrosis (70.4 ± 21.2%). The effects of ambient humidity were found to be insignificant for Turbuhaler and minor for QVAR. CONCLUSIONS: The Idealized Child Throat successfully mimics in vivo deposition data in school age children for the inhalers tested, and may provide a standard platform for optimizing pediatric treatment with inhaled pharmaceutical aerosols.
PURPOSE: Deposition of drug emitted from two commercially available inhalers was measured in an in vitro child oral airway model and compared to existing in vivo data to examine the ability of the child model to replicate in vivo deposition. METHODS: In vitro deposition of drug from a QVAR® pressurized metered dose inhaler (pMDI) and Pulmicort® Turbuhaler® dry powder inhaler (DPI) in an Idealized Child Throat (1) and downstream filter was measured using UV spectroscopy and simulated realistic breathing profiles. Potential effects of ambient relative humidity ranging from 10% to 90% on deposition were also considered. RESULTS: In vitro QVAR pMDI deposition in the idealized mouth-throat at 50% RH (39.2 ± 2.3% of delivered dose) compared well (p>0.05) with in vivo extrathoracic deposition in asthmatic children age 8 to 14 (45.8 ± 12.3%). In vitro Turbuhaler DPI deposition in the idealized mouth-throat at 50% RH (69.0 ± 1.5%) matched in vivo extrathoracic deposition (p>0.05) in 6 to 16 year old children with cystic fibrosis (70.4 ± 21.2%). The effects of ambient humidity were found to be insignificant for Turbuhaler and minor for QVAR. CONCLUSIONS: The Idealized Child Throat successfully mimics in vivo deposition data in school age children for the inhalers tested, and may provide a standard platform for optimizing pediatric treatment with inhaled pharmaceutical aerosols.
Authors: J H Wildhaber; S G Devadason; J M Wilson; C Roller; T Lagana; L Borgström; P N LeSouëf Journal: Eur J Pediatr Date: 1998-12 Impact factor: 3.183
Authors: H A Tiddens; D E Geller; P Challoner; R J Speirs; K C Kesser; S E Overbeek; D Humble; S B Shrewsbury; T A Standaert Journal: J Aerosol Med Date: 2006
Authors: Dale Farkas; Morgan L Thomas; Amr Hassan; Serena Bonasera; Michael Hindle; Worth Longest Journal: Pharm Res Date: 2022-06-27 Impact factor: 4.200
Authors: Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid Journal: J Aerosol Med Pulm Drug Deliv Date: 2016-02-01 Impact factor: 2.849
Authors: Geert-Jan van Geffen; Hielke Markerink; Marc van Barneveld; Frank Verhoeven; Gert Jan Scheffer; Jörgen Bruhn Journal: Med Devices (Auckl) Date: 2021-01-22